Literature DB >> 27568174

The Dutch Measure for quantification of Treatment Resistance in Depression (DM-TRD): an extension of the Maudsley Staging Method.

Frenk P M L Peeters1, Henricus G Ruhe2, Marieke Wichers3, Latifa Abidi1, Karin Kaub4, H Josephine van der Lande4, Jan Spijker5, Marcus J H Huibers6, Aart H Schene7.   

Abstract

BACKGROUND: Treatment resistant depression (TRD) is common in daily practice. An empirical, widely accepted and applicable measure to quantify TRD is lacking. Previously, the Maudsley Staging Method (MSM) showed good validity. We aimed to improve the MSM by refining and extending its items resulting in the Dutch Measure for quantification of TRD (DM-TRD).
METHODS: In addition to duration, severity and failed treatments in the current depressive episode, we added items for functional impairment, comorbid anxiety, personality disorders and psychosocial stressors. We extended the augmentation section and added items for failed psychotherapy and intensified treatment. We examined psychometric properties of the DM-TRD and tested prediction of future depressive symptoms and remission after 16 weeks in 274 (DSM-IV) depressed in- and outpatients entering naturalistic treatment.
RESULTS: The DM-TRD showed excellent inter-/intra-rater reliability. Higher scores were associated with more symptoms and less remission during follow-up. The DM-TRD outperformed the MSM in prediction of future depressive symptomatology. Remission was predicted equally well by both measures. Longer duration of the current episode, larger functional impairment and larger baseline symptom severity were the strongest predictors of symptomatology at follow-up. Longer duration and larger functional impairment were negatively associated with remission. LIMITATIONS: Longer follow-up could have increased predictive power. Addition of items for somatic co-morbidity, childhood adversity and psychotic features must be investigated further.
CONCLUSION: The DM-TRD has excellent psychometric properties and better predictive validity for clinical outcome than other sophisticated measure published to date. Its use in clinical practice and research will improve treatment planning in TRD-patients.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Major depressive disorder; Measurement; Profiling; Treatment resistant depression

Mesh:

Substances:

Year:  2016        PMID: 27568174     DOI: 10.1016/j.jad.2016.08.019

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  19 in total

1.  Current and Common Definitions of Treatment-Resistant Depression: Findings from a Systematic Review and Qualitative Interviews.

Authors:  Sage Brown; Katherine Rittenbach; Sarah Cheung; Gail McKean; Frank P MacMaster; Fiona Clement
Journal:  Can J Psychiatry       Date:  2019-02-14       Impact factor: 4.356

2.  Are Concerns About Irremediableness, Vulnerability, or Competence Sufficient to Justify Excluding All Psychiatric Patients from Medical Aid in Dying?

Authors:  William Rooney; Udo Schuklenk; Suzanne van de Vathorst
Journal:  Health Care Anal       Date:  2018-12

3.  Prevalence and prediction of dropout during depression treatment in routine outpatient care: an observational study.

Authors:  D A van Dijk; M L Deen; Th M van den Boogaard; H G Ruhé; J Spijker; F P M L Peeters
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-10-17       Impact factor: 5.760

4.  Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study.

Authors:  Zhi Nie; Srinivasan Vairavan; Vaibhav A Narayan; Jieping Ye; Qingqin S Li
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

5.  N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.

Authors:  Chenghao Yang; Fokko J Bosker; Jie Li; Robert A Schoevers
Journal:  BMC Psychiatry       Date:  2018-09-04       Impact factor: 3.630

6.  Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review.

Authors:  Wicher A Bokma; Guido A A M Wetzer; Jurriaan B Gehrels; Brenda W J H Penninx; Neeltje M Batelaan; Anton L J M van Balkom
Journal:  Depress Anxiety       Date:  2019-06-23       Impact factor: 6.505

7.  Standardisation framework for the Maudsley staging method for treatment resistance in depression.

Authors:  Abebaw Fekadu; Jacek G Donocik; Anthony J Cleare
Journal:  BMC Psychiatry       Date:  2018-04-11       Impact factor: 3.630

8.  Effectiveness of Emotional Memory Reactivation vs Control Memory Reactivation Before Electroconvulsive Therapy in Adult Patients With Depressive Disorder: A Randomized Clinical Trial.

Authors:  Dominique S Scheepens; Jeroen A van Waarde; Freek Ten Doesschate; Mirjam Westra; Marijn C W Kroes; Aart H Schene; Claudi L H Bockting; Robert A Schoevers; Damiaan A J P Denys; Henricus G Ruhé; Guido A van Wingen
Journal:  JAMA Netw Open       Date:  2020-08-03

9.  Mindfulness-based cognitive therapy for patients with chronic, treatment-resistant depression: A pragmatic randomized controlled trial.

Authors:  Mira B Cladder-Micus; Anne E M Speckens; Janna N Vrijsen; A Rogier T Donders; Eni S Becker; Jan Spijker
Journal:  Depress Anxiety       Date:  2018-08-08       Impact factor: 6.505

10.  Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study.

Authors:  A Kautzky; M Dold; L Bartova; M Spies; G S Kranz; D Souery; S Montgomery; J Mendlewicz; J Zohar; C Fabbri; A Serretti; R Lanzenberger; D Dikeos; D Rujescu; S Kasper
Journal:  Acta Psychiatr Scand       Date:  2018-10-05       Impact factor: 6.392

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.